The stock of Iradimed Corp (NASDAQ:IRMD) is a huge mover today! About 779,008 shares traded hands or 1251.29% up from the average. Iradimed Corp (NASDAQ:IRMD) has declined 4.22% since March 1, 2016 and is downtrending. It has underperformed by 13.47% the S&P500.
The move comes after 8 months negative chart setup for the $116.49M company. It was reported on Oct, 4 by Barchart.com. We have $9.81 PT which if reached, will make NASDAQ:IRMD worth $11.65M less.
Analysts await Iradimed Corp (NASDAQ:IRMD) to report earnings on November, 4. They expect $0.23 earnings per share, up 43.75% or $0.07 from last year’s $0.16 per share. IRMD’s profit will be $2.46 million for 11.85 P/E if the $0.23 EPS becomes a reality. After $0.19 actual earnings per share reported by Iradimed Corp for the previous quarter, Wall Street now forecasts 21.05% EPS growth.
Iradimed Corp (NASDAQ:IRMD) Ratings Coverage
Out of 2 analysts covering iRadimed (NASDAQ:IRMD), 2 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. iRadimed has been the topic of 4 analyst reports since July 30, 2015 according to StockzIntelligence Inc. The stock of Iradimed Corp (NASDAQ:IRMD) earned “Buy” rating by TH Capital on Monday, November 2. The stock has “Buy” rating given by TH Capital on Thursday, July 30. As per Monday, November 2, the company rating was maintained by Roth Capital. The rating was maintained by Roth Capital with “Buy” on Monday, April 4.
According to Zacks Investment Research, “iRadimed Corporation engages in developing, manufacturing, marketing, and distributing magnetic resonance imaging (MRI) compatible products. It offers non-magnetic intravenous (IV) infusion pump systems, IV tubing sets, IV poles, wireless remote displays/controls under the mRidium name; side car pump modules; dose error reduction systems; Masimo SET SpO2 monitoring products; and MRI Pulse oximeters, and MRI oximeter remotes and displays under the iMagox name used during MRI procedures. iRadimed Corporation is headquartered in Winter Park, Florida.”
Insitutional Activity: The institutional sentiment decreased to 1.13 in Q2 2016. Its down 0.27, from 1.4 in 2016Q1. The ratio dived, as 15 funds sold all Iradimed Corp shares owned while 16 reduced positions. 8 funds bought stakes while 27 increased positions. They now own 2.15 million shares or 23.57% less from 2.82 million shares in 2016Q1.
Architects holds 1 shares or 0% of its portfolio. Glenmede Tru Na has 0% invested in the company for 375 shares. The New York-based Bnp Paribas Arbitrage has invested 0% in Iradimed Corp (NASDAQ:IRMD). Morgan Stanley reported 13,732 shares or 0% of all its holdings. Vanguard Gp last reported 224,101 shares in the company. New York State Common Retirement Fund owns 2,600 shares or 0% of their US portfolio. Nationwide Fund Advsrs holds 0% of its portfolio in Iradimed Corp (NASDAQ:IRMD) for 2,215 shares. Federated Invsts Inc Pa holds 0% or 13,974 shares in its portfolio. Tiaa Cref Mgmt Limited holds 0% or 13,484 shares in its portfolio. Ameriprise Fincl Inc reported 59,830 shares or 0% of all its holdings. Strs Ohio last reported 0% of its portfolio in the stock. Moreover, Manufacturers Life The has 0% invested in Iradimed Corp (NASDAQ:IRMD) for 216 shares. Reilly Financial Advsrs Ltd Limited Liability Company, a California-based fund reported 500 shares. Numeric, a Massachusetts-based fund reported 17,800 shares. Millennium Management Ltd Liability Com has invested 0% of its portfolio in Iradimed Corp (NASDAQ:IRMD).
Insider Transactions: Since June 9, 2016, the stock had 0 insider purchases, and 4 insider sales for $564,366 net activity. ALLEN MONTY K also sold $42,931 worth of Iradimed Corp (NASDAQ:IRMD) shares. Waldman Louis S. sold 23,162 shares worth $440,078. Nardi Steven M. also sold $35,857 worth of Iradimed Corp (NASDAQ:IRMD) shares.
More notable recent Iradimed Corp (NASDAQ:IRMD) news were published by: Streetinsider.com which released: “Iradimed Corp. (IRMD) Cuts Q3, FY16 Outlook” on October 04, 2016, also Benzinga.com with their article: “12 Biggest Mid-Day Losers For Tuesday” published on October 04, 2016, Seekingalpha.com published: “IRadimed Corp. (IRMD) CEO Roger Susi on Q2 2016 Results – Earnings Call Transcript” on July 31, 2016. More interesting news about Iradimed Corp (NASDAQ:IRMD) were released by: Seekingalpha.com and their article: “iRadimed Corporation – MRI Compatible IV Infusion Pump Quickly Becoming A …” published on August 16, 2016 as well as Seekingalpha.com‘s news article titled: “iRadimed: A Niche Medical Device Company With 55%+ Upside Potential” with publication date: August 17, 2016.
IRMD Company Profile
IRADIMED CORPORATION (IRADIMED), incorporated on April 8, 2014, develops, makes, markets and distributes Magnetic Resonance Imaging (MRI) compatible products, and provides non-magnetic intravenous (IV) infusion pump systems. The Firm operates through development, manufacture and sale of MRI compatible products and IV infusion pump systems for use by hospitals and acute care facilities during MRI procedures segment. The Company’s MRidium MRI compatible IV infusion pump system has been designed with a non-magnetic ultrasonic motor, non-ferrous parts and other features in order to deliver anesthesia and other IV fluids during various MRI procedures. Each system consists of MRidium MRI compatible IV infusion pump, non-magnetic mobile stand and disposable IV tubing sets.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.